I'm LongbridgeAI, I can summarize articles.BillionToOne reported Q2 FY26 revenue of $109.4 million, a 64% year-over-year increase, with net income turning positive at $8.1 million. Operating income reached $5.5 million, and gross margin widened to 70%. Prenatal testing revenue rose 55% to $94.2 million, while oncology testing more than doubled to $13.7 million. The company reiterated its full-year revenue guidance of $450-$465 million and plans to launch the Unity Fetal Risk Screen on August 17, 2026.
- BillionToOne posted Q2 2026 revenue of $109.4 million, up 64% year over year. * Operating income was $5.5 million, swinging from an operating loss a year earlier; net income was $8.1 million, or $0.15 per diluted share. * Gross margin widened 5 percentage points to 70%; tests delivered rose 35% to 196,000. * Prenatal testing revenue rose 55% to $94.2 million; oncology testing revenue more than doubled to $13.7 million. * Reiterated 2026 revenue guidance of $450 million-$465 million; plans Unity Fetal Risk Screen 130-gene panel launch Aug. 17, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here